[Clinical importance of determining the content of surface-active substances in the amniotic fluid in complicated pregnancy].
D000293:Adolescent; D000328:Adult; D000653:Amniotic Fluid / Q000032:analysis*; D001787:Blood Group Incompatibility / Q000378:metabolism; D005260:Female; D005323:Fetal Monitoring / Q000379:methods; D006801:Humans; D007674:Kidney Diseases / Q000378:metabolism; D008168:Lung / Q000254:growth & development; D010743:Phospholipids / Q000032:analysis; D011225:Pre-Eclampsia / Q000378:metabolism; D011247:Pregnancy; D011248:Pregnancy Complications / Q000378:metabolism*; D011254:Pregnancy in Diabetics / Q000378:metabolism; D012204:Rh-Hr Blood-Group System; D013501:Surface-Active Agents / Q000032:analysis*
D010743:Phospholipids; D012204:Rh-Hr Blood-Group System; D013501:Surface-Active Agents
Klinicheskoe znachenie opredeleniia soderzhaniia poverkhnostno-aktivnykh veshchestv v amnioticheskoĭ zhidkosti pri oslozhnennoĭ beremennosti.